NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis $5.06 -0.23 (-4.35%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Exscientia Stock (NASDAQ:EXAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exscientia alerts:Sign Up Key Stats Today's Range$5.04▼$5.4150-Day Range$4.58▼$6.0052-Week Range$3.80▼$7.91Volume577,434 shsAverage Volume644,563 shsMarket Capitalization$611.69 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingHold Company OverviewExscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More… Publisher makes HUGE discovery (Ad)TradingPub Publisher Nate Tucci recently sat down with Chris Pulver to learn about the $100 Challenge. Chris walked him through the trade on a private Zoom call… And he was very clear… This wasn’t a “get rich quick” penny stock scheme… Or an AI stock picker that “cracked the code” of the stock market… It was just a simple, daily trade that anyone could set up at about 9:40 in the morning to target $100 a day or more (starting with just $1,000)...Sign up here to save your seat and learn more Exscientia Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks51st Percentile Overall ScoreEXAI MarketRank™: Exscientia scored higher than 51% of companies evaluated by MarketBeat, and ranked 630th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingExscientia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 2 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.25) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Exscientia has recently decreased by 9.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.70% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Exscientia has recently decreased by 9.69%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.65 News SentimentExscientia has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exscientia this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for EXAI on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAI Stock News HeadlinesVet tranquillizer increases overdose deaths in Yukon, health minister saysOctober 12, 2024 | msn.comBoeing Sacks 17,000 Workers Amid Strike and Safety ConcernsOctober 12, 2024 | nz.finance.yahoo.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…October 18, 2024 | WealthPress (Ad)Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug DiscoveryOctober 12, 2024 | msn.comCapricor reports positive long-term data for DMD drug deramiocelOctober 11, 2024 | msn.comExscientia Set for Strategic Acquisition by RecursionOctober 11, 2024 | finance.yahoo.comRecursion, Exscientia seek support for merger ahead of special meetingOctober 10, 2024 | seekingalpha.comExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024October 9, 2024 | businesswire.comSee More Headlines EXAI Stock Analysis - Frequently Asked Questions How have EXAI shares performed this year? Exscientia's stock was trading at $6.41 at the beginning of the year. Since then, EXAI stock has decreased by 21.1% and is now trading at $5.06. View the best growth stocks for 2024 here. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings data on Thursday, August, 15th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The company earned $5.60 million during the quarter. Exscientia had a negative net margin of 620.99% and a negative trailing twelve-month return on equity of 37.56%. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share. How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exscientia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/15/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+38.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-620.99% Pretax Margin-656.65% Return on Equity-37.56% Return on Assets-26.19% Debt Debt-to-Equity Ratio0.06 Current Ratio5.93 Quick Ratio5.93 Sales & Book Value Annual Sales$21.02 million Price / Sales29.10 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.38Miscellaneous Outstanding Shares120,887,000Free Float101,062,000Market Cap$611.69 million OptionableOptionable Beta0.84 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EXAI) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.